CSIMarket
 


Penumbra Inc  (PEN)
Other Ticker:  
 
 

PEN's Revenue Growth by Quarter and Year

Penumbra Inc's Revenue results by quarter and year




PEN Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 284.68 221.22 204.01
III Quarter September - 270.95 213.68 190.12
II Quarter June - 261.50 208.34 184.26
I Quarter March 278.66 241.40 203.90 169.20
FY   278.66 1,058.53 847.14 747.59



PEN Revenue first quarter 2024 Y/Y Growth Comment
Penumbra Inc reported Revenue increase of 15.43% year on year in the first quarter 2024, to $ 278.66 millions, this is lower than Penumbra Inc's recent average Revenue improvement of 29.76%.

Looking into first quarter 2024 results within Medical Equipment & Supplies industry 56 other companies have achieved higher Revenue growth. While Penumbra Inc' s Revenue growth of 15.43% ranks overall at the positon no. 955 in the first quarter 2024.




PEN Revenue ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - 28.69 % 8.44 % 22.23 %
III Quarter September - 26.8 % 12.39 % 25.84 %
II Quarter June - 25.52 % 13.07 % 75.3 %
I Quarter March 15.43 % 18.39 % 20.51 % 23.21 %
FY   - 24.95 % 13.32 % 33.4 %

Financial Statements
Penumbra Inc's first quarter 2024 Revenue $ 278.66 millions PEN's Income Statement
Penumbra Inc's first quarter 2023 Revenue $ 241.40 millions Quarterly PEN's Income Statement
New: More PEN's historic Revenue Growth >>


PEN Revenue (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - 5.07 % 3.53 % 7.31 %
III Quarter September - 3.61 % 2.56 % 3.18 %
II Quarter June - 8.33 % 2.18 % 8.9 %
I Quarter March -2.12 % 9.12 % -0.05 % 1.38 %
FY (Year on Year)   - 24.95 % 13.32 % 33.4 %




Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #57
Healthcare Sector #169
Overall #955

Revenue Y/Y Growth Statistics
High Average Low
139.05 % 29.76 % 2.38 %
(Jun 30 2017)  
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #57
Healthcare Sector #169
Overall #955
Revenue Y/Y Growth Statistics
High Average Low
139.05 % 29.76 % 2.38 %
(Jun 30 2017)  

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Penumbra Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
43.73 % 5.44 % -23.46 %
(Sep 30 2020)  


PEN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Penumbra Inc reported fall in Revenue from the fourth quarter by -2.12% to $ 278.66 millions, from $ 284.68 millions released in the previous quarter.

Albeit periodic influence usually energize I. Quarter 2024 results, this clearly could not be enough to recover Penumbra Inc's performance, Daniel Gutiérrez, Healthcare sector advisor based in Valencia said and continued that average quarter on quarter Revenue growth is at 5.44% for Penumbra Inc.

Within Medical Equipment & Supplies industry 68 other companies have achieved higher Revenue quarter on quarter growth. While Penumbra Inc's Revenue growth quarter on quarter, overall rank is 1547.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #69
Healthcare Sector #193
Overall #1547
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #69
Healthcare Sector #193
Overall #1547
Revenue Q/Q Growth Statistics
High Average Low
43.73 % 5.44 % -23.46 %
(Sep 30 2020)  


PEN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Penumbra Inc reported fall in Revenue from the previous quarter by -2.12% to $ 278.66 millions, from $ 284.68 millions released a quarter before.

Some cyclical influence have not recover the I. Quarter for the Penumbra Inc, Daniel Gutiérrez, Healthcare sector advisor based in Valencia pointed out, he cited little pessimism towards Penumbra Inc's outlook.

Within Medical Equipment & Supplies industry 68 other companies have achieved higher Revenue quarter on quarter growth. While Penumbra Inc's Revenue growth quarter on quarter, overall rank is 1547.


Penumbra Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 1,095.78 $ 1,058.52 $ 995.06 $ 937.79 $ 884.64
Y / Y Revenue Growth (TTM) 23.87 % 24.95 % 19.9 % 16.3 % 13.08 %
Year on Year Revenue Growth Overall Ranking # 519 # 614 # 996 # 1008 # 314
Seqeuential Revenue Change (TTM) 3.52 % 6.38 % 6.11 % 6.01 % 4.43 %
Seq. Revenue Growth (TTM) Overall Ranking # 955 # 1289 # 1959 # 2227 # 1997




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2024 period, Penumbra Inc's cumulative twelve months Revenue were $ 1,096 millions, company would post below average annual Revenue growth of 4.43% year on year, if the fiscal year would end at Mar 31 2024.
A slow-down in the Penumbra Inc's Revenue growth from the 284.68% growth in Dec 31 2023.

In the Healthcare sector 115 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 519, from total ranking in previous quarter at 614.

Revenue TTM Q/Q Growth Statistics
High Average Low
139.05 %
29.76 %
2.38 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 57
Healthcare Sector # 116
Overall # 519

Revenue TTM Y/Y Growth Statistics
High Average Low
139.05 %
29.76 %
2.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 57
Sector # 169
S&P 500 # 955
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2024 period, Penumbra Inc's cumulative twelve months Revenue were $ 1,096 millions, company would post below average annual Revenue growth of 2.38% year on year, if the fiscal year would end at Mar 31 2024.
A slow-down in the Penumbra Inc's Revenue growth from the 284.68% growth in Dec 31 2023.

In the Healthcare sector 115 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 519, from total ranking in previous quarter at 614.

Revenue TTM Q/Q Growth Statistics
High Average Low
139.05 %
29.76 %
2.38 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 57
Healthcare Sector # 116
Overall # 519

Revenue TTM Y/Y Growth Statistics
High Average Low
139.05 %
29.76 %
2.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 57
Sector # 169
S&P 500 # 955




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PEN's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for PEN's Competitors
Revenue Growth for Penumbra Inc's Suppliers
Revenue Growth for PEN's Customers

You may also want to know
PEN's Annual Growth Rates PEN's Profitability Ratios PEN's Asset Turnover Ratio PEN's Dividend Growth
PEN's Roe PEN's Valuation Ratios PEN's Financial Strength Ratios PEN's Dividend Payout Ratio
PEN's Roa PEN's Inventory Turnover Ratio PEN's Growth Rates PEN's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Eli Lilly And Company25.98%$ 25.977 millions
Optinose Inc 25.61%$ 25.612 millions
Twist Bioscience Corporation25.13%$ 25.128 millions
Vericel Corporation25.02%$ 25.024 millions
Pulmonx Corporation24.38%$ 24.376 millions
The Oncology Institute Inc 24.25%$ 24.247 millions
Dexcom Inc 24.19%$ 24.194 millions
The Pennant Group Inc 24.08%$ 24.079 millions
Lipella Pharmaceuticals Inc 23.58%$ 23.577 millions
Insulet Corporation23.35%$ 23.345 millions
Cadre Holdings inc 23.16%$ 23.159 millions
Lantheus Holdings Inc 22.96%$ 22.961 millions
Amphastar Pharmaceuticals Inc 22.72%$ 22.721 millions
Neurocrine Biosciences Inc 22.57%$ 22.574 millions
Inari Medical Inc 22.50%$ 22.497 millions
Xeris Biopharma Holdings Inc 22.42%$ 22.418 millions
Insmed Inc22.27%$ 22.269 millions
Amgen Inc 21.98%$ 21.982 millions
Precipio inc 21.83%$ 21.832 millions
Helius Medical Technologies inc 21.62%$ 21.622 millions
Armata Pharmaceuticals Inc 21.36%$ 21.357 millions
Halozyme Therapeutics Inc 20.81%$ 20.806 millions
Neuropace Inc 19.84%$ 19.838 millions
Jaguar Health Inc 19.22%$ 19.219 millions
Zevra Therapeutics Inc 18.96%$ 18.965 millions
Cytek Biosciences Inc 18.67%$ 18.672 millions
Mersana Therapeutics inc 18.50%$ 18.495 millions
Silk Road Medical Inc 18.36%$ 18.365 millions
Atrion Corporation18.36%$ 18.356 millions
Amneal Pharmaceuticals Inc 18.28%$ 18.284 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com